Skip to main content

Advertisement

Table 2 Adverse events during MASCT treatment

From: Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy

Adverse events DC injection T cell injection
Treatment times (n = 71) Patients Treatment times (n = 100) Patients
Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) n = 13 (%) Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) n = 13 (%)
Constitutional symptoms
 Fever 2 (2.8) 0 (0) 0 (0) 0 (0) 2 (15.4) 1 (1) 0 (0) 0 (0) 0 (0) 1 (7.7)
Musculoskeletal disorders
 Osteodynia 1 (1.4) 0 (0) 0 (0) 0 (0) 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Respiratory tract disorders
 Cough 1 (1.4) 0 (0) 0 (0) 0 (0) 1 (7.7) 3 (3) 0 (0) 0 (0) 0 (0) 2 (15.4)
 Throat 1 (1.4) 0 (0) 0 (0) 0 (0) 1 (7.7) 3 (3) 0 (0) 0 (0) 0 (0) 2 (15.4)
Blood examinations
 White blood cell decrease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (7.7)
 Platelet decrease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 0 (0) 0 (0) 2 (15.4)
 Neutrophil decrease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 (7.7)
 Hemoglobin decrease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 1 (7.7)
Immune diseases
 Allergic reaction 2 (2.8) 0 (0) 0 (0) 0 (0) 2 (15.4) 3 (3) 0 (0) 0 (0) 0 (0) 2 (15.4)
  1. The grades of adverse events are defined according to common terminology criteria for adverse events (CTCAE)